Matches in SemOpenAlex for { <https://semopenalex.org/work/W2531736191> ?p ?o ?g. }
- W2531736191 endingPage "1173" @default.
- W2531736191 startingPage "1157" @default.
- W2531736191 abstract "Poly(ADP-ribose) polymerase (PARP) inhibitors cause targeted tumour cell death in homologous recombination (HR)-deficient cancers, including BRCA-mutated tumours, by exploiting synthetic lethality. PARP inhibitors are being evaluated in late-stage clinical trials of ovarian cancer (OC). Recently, olaparib was the first PARP inhibitor approved in the European Union and United States for the treatment of advanced BRCA-mutated OC. This paper reviews the role of BRCA mutations for tumorigenesis and PARP inhibitor sensitivity, and summarises the clinical development of PARP inhibitors for the treatment of patients diagnosed with OC. Among the five key PARP inhibitors currently in clinical development, olaparib has undergone the most extensive clinical investigation. PARP inhibitors have demonstrated durable antitumour activity in BRCA-mutated advanced OC as a single agent in the treatment and maintenance setting, particularly in platinum-sensitive disease. PARP inhibitors are well tolerated; however, further careful assessment of moderate and late-onset toxicity is mandatory in the maintenance and adjuvant setting, respectively. PARP inhibitors are also being evaluated in combination with chemotherapeutic and novel targeted agents to potentiate antitumour activities. Current research is extending the use of PARP inhibitors beyond BRCA mutations to other sensitising molecular defects that result in HR-deficient cancer, and is defining an HR-deficiency signature. Trials are underway to determine whether such a signature will predict sensitivity to PARP inhibitors in women with sporadic OC." @default.
- W2531736191 created "2016-10-21" @default.
- W2531736191 creator A5062837404 @default.
- W2531736191 creator A5088144652 @default.
- W2531736191 date "2016-10-13" @default.
- W2531736191 modified "2023-10-06" @default.
- W2531736191 title "PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions" @default.
- W2531736191 cites W1483751849 @default.
- W2531736191 cites W1605052148 @default.
- W2531736191 cites W1661254177 @default.
- W2531736191 cites W171848694 @default.
- W2531736191 cites W182695913 @default.
- W2531736191 cites W1844286590 @default.
- W2531736191 cites W1912177776 @default.
- W2531736191 cites W1968960110 @default.
- W2531736191 cites W1970184435 @default.
- W2531736191 cites W1971419576 @default.
- W2531736191 cites W1973268287 @default.
- W2531736191 cites W1973695302 @default.
- W2531736191 cites W1975548607 @default.
- W2531736191 cites W1980721628 @default.
- W2531736191 cites W1984087886 @default.
- W2531736191 cites W1984745078 @default.
- W2531736191 cites W1985804387 @default.
- W2531736191 cites W1989006164 @default.
- W2531736191 cites W1989185017 @default.
- W2531736191 cites W1989362916 @default.
- W2531736191 cites W1991182906 @default.
- W2531736191 cites W1999659306 @default.
- W2531736191 cites W2000234236 @default.
- W2531736191 cites W2002962154 @default.
- W2531736191 cites W2003027334 @default.
- W2531736191 cites W2004935367 @default.
- W2531736191 cites W2009007206 @default.
- W2531736191 cites W2009174760 @default.
- W2531736191 cites W2014599726 @default.
- W2531736191 cites W2015360671 @default.
- W2531736191 cites W2023357234 @default.
- W2531736191 cites W2026409525 @default.
- W2531736191 cites W2030093162 @default.
- W2531736191 cites W2031821561 @default.
- W2531736191 cites W2033761616 @default.
- W2531736191 cites W2033816200 @default.
- W2531736191 cites W2045153367 @default.
- W2531736191 cites W2050164541 @default.
- W2531736191 cites W2056848326 @default.
- W2531736191 cites W2057858099 @default.
- W2531736191 cites W2060728805 @default.
- W2531736191 cites W2062154047 @default.
- W2531736191 cites W2062568878 @default.
- W2531736191 cites W2065849886 @default.
- W2531736191 cites W2067818013 @default.
- W2531736191 cites W2070721014 @default.
- W2531736191 cites W2070758111 @default.
- W2531736191 cites W2072528578 @default.
- W2531736191 cites W2073931597 @default.
- W2531736191 cites W2074952360 @default.
- W2531736191 cites W2076746363 @default.
- W2531736191 cites W2077436902 @default.
- W2531736191 cites W2079157714 @default.
- W2531736191 cites W2079891276 @default.
- W2531736191 cites W2083431317 @default.
- W2531736191 cites W2083960841 @default.
- W2531736191 cites W2086038769 @default.
- W2531736191 cites W2094666871 @default.
- W2531736191 cites W2094739761 @default.
- W2531736191 cites W2096391864 @default.
- W2531736191 cites W2097984332 @default.
- W2531736191 cites W2098737737 @default.
- W2531736191 cites W2102004732 @default.
- W2531736191 cites W2102971019 @default.
- W2531736191 cites W2104425537 @default.
- W2531736191 cites W2106390123 @default.
- W2531736191 cites W2106729876 @default.
- W2531736191 cites W2106951948 @default.
- W2531736191 cites W2109465247 @default.
- W2531736191 cites W2109772731 @default.
- W2531736191 cites W2110017381 @default.
- W2531736191 cites W2110137106 @default.
- W2531736191 cites W2111437716 @default.
- W2531736191 cites W2112241575 @default.
- W2531736191 cites W2113382133 @default.
- W2531736191 cites W2113467627 @default.
- W2531736191 cites W2117959909 @default.
- W2531736191 cites W2117964602 @default.
- W2531736191 cites W2118211359 @default.
- W2531736191 cites W2120574701 @default.
- W2531736191 cites W2120806256 @default.
- W2531736191 cites W2123215808 @default.
- W2531736191 cites W2123696077 @default.
- W2531736191 cites W2124322375 @default.
- W2531736191 cites W2124470568 @default.
- W2531736191 cites W2128746885 @default.
- W2531736191 cites W2130078242 @default.
- W2531736191 cites W2130084494 @default.
- W2531736191 cites W2131978108 @default.
- W2531736191 cites W2132396299 @default.
- W2531736191 cites W2135525536 @default.